Contreras-Chávez Gerson G, Zapi-Colin Luis A, Estrada José A, Contreras Irazú, Estrada José A
Neurochemistry Laboratory, Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca, México.
Neurochemistry Laboratory, Faculty of Medicine, Universidad Autónoma del Estado de México, Paseo Tollocan esq. Jesús Carranza s/n, Colonia Moderna de la Cruz, Toluca, C.P. 50180, México.
Mol Biol Rep. 2025 Feb 5;52(1):207. doi: 10.1007/s11033-025-10312-w.
Glioblastoma multiforme is the most common and aggressive malignant brain tumor. Current therapies have been unable to improve life expectancy in patients. This cancer is frequently accompanied by overexpression of receptors, such as EGFR, VEGFR and TLRs, involved in the regulation of inflammation, cell proliferation, differentiation, and survival. The present review summarizes current knowledge from preclinical and clinical studies investigating the role of pattern recognition and tyrosine kinase receptors in glioblastoma development and evolution, and their possible use to improve treatment outcomes and patient survival.
多形性胶质母细胞瘤是最常见且侵袭性最强的恶性脑肿瘤。目前的治疗方法未能提高患者的预期寿命。这种癌症常伴有受体的过表达，如表皮生长因子受体（EGFR）、血管内皮生长因子受体（VEGFR）和Toll样受体（TLRs），这些受体参与炎症、细胞增殖、分化和存活的调节。本综述总结了临床前和临床研究的现有知识，这些研究探讨了模式识别受体和酪氨酸激酶受体在胶质母细胞瘤发生发展中的作用，以及它们在改善治疗效果和患者生存率方面的潜在用途。
